On June 12, SpaceX (NASDAQ: SPCX) had the biggest IPO on record, making $75 billion (1) \u2014 but shares are already dropping (2). Entrepreneur and NYU professor Scott Galloway isn\u2019t impressed.<\/p>\n
\u201cGetting the Nasdaq to waive requirements applied to every company until now, so he can force index funds to purchase shares, aims a demand cannon of $75B at a business with a small float. The result is a price that in no way reflects the underlying value,\u201d wrote Galloway in a June 17 Medium post (3). \u201cBut I digress. This isn\u2019t an investment, but a trade. So \u2026 where to \u2018invest\u2019?\u201d<\/p>\n
Must Read <\/p>\n
Galloway says you should forget SpaceX stock and invest in GLP-1s instead.<\/p>\n
\u201cFive years ago, when Ozempic and Wegovy were first approved for weight loss, GLP-1s looked like a silver bullet for obesity,\u201d Galloway wrote. \u201cToday, they\u2019re a fully loaded magazine of silver bullets aimed at obesity, addiction, cancer, sleep apnea, and a growing list of other diseases and chronic conditions.\u201d<\/p>\n
Here\u2019s what Galloway had to say about which GLP-1 producers make for a good investment \u2014 and what needs to change for GLP-1s to be even more successful.<\/p>\n
Eli Lilly is performing especially well in the GLP-1 market <\/p>\n
Galloway says that the pharmaceutical company Eli Lilly is doing especially well thanks to the weight loss drug.<\/p>\n
He says that Eli Lilly\u2019s shares have seen a 418% price increase since 2021, when GLP-1s were approved for weight loss. According to Eli Lilly\u2019s historic price lookup page, its stock price was $276.22 at the end of 2021. By the end of 2025, its stock was worth $1,074.68 (4).<\/p>\n
The company is currently working on a new GLP-1 drug, a combination drug with promising phase 3 results (5). If successful, this medication could help Eli Lilly\u2019s stock climb even higher.<\/p>\n
In comparison, fellow GLP-1 creator Novo Nordisk hasn\u2019t seen the same level of success. Galloway says that might be because Eli Lilly has had a better time marketing directly to consumers.<\/p>\n
\u201cIn the GLP-1 category, we observe prices are elastic. The more we lower the price, the more users we get,\u201d says Eli Lilly Chair and CEO David Ricks. \u201cThat\u2019s the path we\u2019re on.\u201d<\/p>\n
Galloway also says that GLP-1s almost work like a subscription, because people who get on them tend to stay on them.<\/p>\n
Read More: Robert Kiyosaki has a grim warning for baby boomers. This is what he recommends to protect your wealth<\/a><\/strong><\/p>\n The hardest sell for GLP-1s is the price <\/p>\n The main reason people stop taking GLP-1s is the price, according to the Cleveland Clinic (6).<\/p>\n GLP-1s are expensive, costing hundreds of dollars per month (7) or more. And increasingly, insurance isn\u2019t agreeing to pay for it (8). Lowering drug prices provides real support for people who were previously accessing the drug through their insurance before losing coverage.<\/p>\n Eli Lilly has partnered with the U.S. government to allow seniors on Medicaid D to pay only $50 per month for the drug (9). It\u2019s also offered self-pay options for patients who are uninsured, or whose insurance won\u2019t cover it \u2014 but its prices are still expensive, requiring people to pay up to $449 per multi-dose pen.<\/p>\n \u201cThe GLP-1 story offers something Silicon Valley used to produce in abundance: a hopeful vision of the future,\u201d says Galloway. \u201cThe question isn\u2019t whether GLP-1s will change the U.S. They already have. The question is whether we\u2019ll be stupid enough to ration the change.\u201d<\/p>\n You May Also Like <\/p>\n Join 250,000+ readers and get Moneywise\u2019s best stories and exclusive interviews first \u2014 clear insights curated and delivered weekly. Subscribe now.<\/a><\/strong><\/p>\n Article Sources <\/p>\n We rely only on vetted sources and credible third-party reporting. For details, see our ethics and guidelines<\/a>.<\/p>\n NPR (1<\/a>), (8<\/a>); Reuters (2<\/a>); Medium (3<\/a>); Eli Lilly and Company (4<\/a>), (5<\/a>), (9<\/a>); Cleveland Clinic (6<\/a>); Maven Clinic (7<\/a>)<\/p>\n This article originally appeared on Moneywise.com<\/a> under the title: Scott Galloway says GLP-1 drugs are a ‘silver bullet’ for America’s woes, if we’re not ‘stupid enough’ to get in the way<\/a><\/p>\n This article provides information only and should not be construed as advice. It is provided without warranty of any kind.<\/p>\n","protected":false},"excerpt":{"rendered":"On June 12, SpaceX (NASDAQ: SPCX) had the biggest IPO on record, making $75 billion (1) \u2014 but…\n","protected":false},"author":3,"featured_media":880599,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[25996,222061,210,1060,190627,357767,67,132,68],"class_list":["post-880598","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-eli-lilly","tag-galloway","tag-health","tag-medication","tag-scott-galloway","tag-silver-bullet","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116782698764453056","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/880598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=880598"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/880598\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/880599"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=880598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=880598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=880598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}